Cirsimaritin

Research use only, not for human use.

Cirsimaritin exhibits antibacterial, anti-inflammation, anti-tumor, antioxidant properties and renal protection. Cirsimaritin binds weakly to the benzodiazepine site on GABAA receptors.

Cirsimaritin exhibits antibacterial, anti-inflammation, anti-tumor, antioxidant properties and renal protection. Cirsimaritin binds weakly to the benzodiazepine site on GABAA receptors.(In Vitro):Cirsimaritin inhibits the growth of tumor cells and induced mitochondrial apoptosis in human gallbladder carcinoma cell line (GBC-SD), it triggers endoplasmic reticulum (ER) stress and down-regulates the phosphorylation of Akt . Cirsimaritin increases tyrosinase activity and melanin content in murine B16F10 melanoma cells by activation of CREB as well as upregulation of MITF and tyrosinase expression in a dose-dependent manner .(In Vivo):Cirsimaritin significantly reduces anxiety in mice. The high-affinity benzodiazepine binding site is not involved in the anxiolytic activity induced by these compounds. Cirsimaritin does not decrease by co-administration of flumazenil (2.5 mg/kg) with salvigenin, rosmanol and cirsimaritin (10 mg/kg).

——

Cirsimaritin significantly reduces the anxiety in mice. Cirsimaritin does not decrease by co-administration of flumazenil (2.5 mg/kg) with salvigenin, rosmanol and cirsimaritin (10 mg/kg), indicating that the high-affinity benzodiazepine binding site is not involved in the anxiolytic activity induced by these compounds.

——

Others

Other Targets

——

——

——

6601-62-3

314.293

C17H14O6

>98% (HPLC)

In Vitro:?DMSO : 22.73 mg/mL (72.32 mM)

COc1cc2oc(cc(=O)c2c(O)c1OC)-c1ccc(O)cc1

——

(-20℃)

With Ice Pack

≥ 2 years